What Is Ibogaine? Uses, Effects, Risks and Legal Status

*Ibogaine is a naturally occurring psychoactive alkaloid extracted from the root bark of Tabernanthe iboga, a shrub native to Central West Africa.* In medicine it is studied mainly as a single-dose treatment that can interrupt opioid withdrawal and reduce cravings, and more recently for PTSD and traumatic brain injury. It is not approved by the FDA, it carries real cardiac risk, and it should only be given under continuous medical and cardiac monitoring.

Key takeaways

• Ibogaine comes from the iboga root and has been used for centuries in the Bwiti spiritual tradition of Gabon and Cameroon.
• Its anti-addictive effect was first described in 1962 by Howard Lotsof, who noticed his heroin withdrawal and cravings had disappeared after taking it.
• It acts on several brain systems at once (opioid, NMDA, serotonin and nicotinic receptors), which is why it behaves very differently from replacement drugs such as methadone.
• The liver converts it into noribogaine, a long-acting metabolite that stays in the body for days.
• The main medical risk is a temporary prolongation of the heart's QT interval, which can trigger dangerous arrhythmias without proper screening and monitoring.
• It is a Schedule I substance in the United States, but it is not a controlled substance in Mexico, where medically supervised clinics operate.

Where ibogaine comes from

The iboga shrub grows in the rainforests of Gabon, Cameroon and the Republic of the Congo. For generations, practitioners of the Bwiti tradition have used the root bark in initiation and healing ceremonies. The main active compound, ibogaine, was isolated by French chemists in the early 1900s and was briefly sold in France as a mild stimulant.

Western interest in ibogaine as an addiction treatment began in 1962, when Howard Lotsof, then a young man dependent on heroin, took it and found that his withdrawal symptoms and desire to use were gone the following day. He spent the rest of his life advocating for research, and his observations led to decades of animal studies and, later, observational studies in humans.

How ibogaine works in the brain

Most addiction medicines work on a single receptor. Ibogaine is unusual because it interacts with several systems at the same time:

• Opioid receptors: it acts on kappa and mu opioid receptors in a way that appears to relieve withdrawal without producing the euphoria of an opioid.
• NMDA receptors: it blocks these glutamate receptors, a mechanism linked to reduced tolerance and cravings.
• Serotonin and dopamine transporters: it changes how these mood and reward chemicals are recycled.
• Nicotinic receptors: it blocks alpha-3 beta-4 nicotinic receptors, which are involved in reward and withdrawal pathways.

After ingestion, the liver enzyme CYP2D6 converts ibogaine into noribogaine, which remains active for days and is thought to contribute to the lower mood, cravings and anxiety many patients describe in the weeks after treatment. Animal studies also show ibogaine increases neurotrophic factors such as GDNF and BDNF, proteins involved in neuroplasticity, although this has not yet been confirmed in controlled human trials.

What ibogaine is used for

Opioid use disorder

The most studied use is opioid dependence, including heroin, prescription painkillers and fentanyl. Observational studies from Mexico and New Zealand report that a single treatment markedly reduced withdrawal symptoms, and that a meaningful share of patients stopped or reduced opioid use in the following months. These studies are small and uncontrolled, so the results are promising but not definitive. We compare this approach to maintenance drugs in Ibogaine vs. Methadone and Suboxone.

PTSD, depression and traumatic brain injury

In January 2024, researchers at Stanford University published a study in Nature Medicine on 30 U.S. special operations veterans with traumatic brain injury who were treated with ibogaine combined with magnesium at a clinic in Mexico. One month later, participants showed large improvements in disability, PTSD, depression and anxiety scores, with no serious adverse events. Stories like that of Navy SEAL Marcus Capone, featured in TIME, have driven public interest, and in June 2025 Texas approved $50 million in state funding for ibogaine clinical trials.

Other substances

Ibogaine has also been explored for alcohol, cocaine, methamphetamine and nicotine dependence. Evidence here is more limited. Importantly, people dependent on alcohol or benzodiazepines need a full medical detox before ibogaine, because withdrawal from those substances can cause seizures.

What the experience is like

Ibogaine is a long-acting treatment. In a medical setting, the main session usually unfolds in three phases:

1. Acute phase (roughly 4 to 8 hours): dream-like visual experiences, often a review of memories, with eyes closed, while lying still. Nausea and loss of coordination are common.
2. Evaluative phase (8 to 20 hours): visions fade and patients reflect on what they experienced. Sleep is difficult.
3. Residual phase (24 to 72 hours): fatigue, sensitivity to light and sound, and a gradual return of energy. Some people describe low mood during this "gray day."

This is why reputable programs last about a week: the session itself is only one part of a process that includes preparation, recovery and integration.

Risks and safety

Ibogaine is not a benign substance. The most serious risk is cardiac: it blocks hERG potassium channels in the heart, which lengthens the QT interval and can lead to life-threatening arrhythmias. A 2012 forensic review documented 19 deaths associated with ibogaine between 1990 and 2008, most involving pre-existing heart disease, drug interactions or no medical supervision. Other risks include seizures (especially during alcohol or benzodiazepine withdrawal), dangerous interactions with medications, and psychiatric reactions in people with bipolar disorder or psychosis.

Safety depends on screening out high-risk patients and monitoring the heart continuously. Read our full guide to ibogaine side effects and heart safety.

Is ibogaine legal?

• United States: Schedule I controlled substance; it cannot be prescribed. Research funding is growing, including at the state level.
• Mexico: ibogaine is not listed as a controlled substance, which is why most clinics serving North American patients are located there. Quality varies widely between facilities.
• Canada: not approved for sale, and it cannot be administered legally outside approved research.
• New Zealand: can be prescribed by a doctor as an unapproved medicine.
• Brazil: some states allow use under medical supervision.

Frequently asked questions

Is ibogaine a psychedelic?

Yes, ibogaine is usually classified as a psychedelic or oneirogen (dream-inducing substance). Unlike psilocybin or LSD, its experience is typically introspective and dream-like, lasts much longer, and has significant physical effects on the heart.

How many ibogaine treatments are needed?

Most medical programs use a single main session, sometimes preceded by a small test dose. Some patients receive a lower "booster" dose weeks or months later, but this is decided case by case by the medical team.

Does ibogaine cure addiction?

No medicine cures addiction on its own. Ibogaine can interrupt withdrawal and reduce cravings, creating a window in which change is easier. Long-term results depend heavily on aftercare, therapy and changes in environment.

Who should not take ibogaine?

People with heart disease, a personal or family history of long QT syndrome or sudden cardiac death, significant liver disease, active psychosis or bipolar disorder, and pregnant women should not take ibogaine. Many medications must be stopped safely beforehand. A full medical screening is essential.

References

• Oaklander, M. "Inside Ibogaine, One of the Most Promising and Perilous Psychedelics for Addiction." TIME, 2021.
• Cherian, K. N. et al. "Magnesium–ibogaine therapy in veterans with traumatic brain injuries." Nature Medicine, 2024.
• Koenig, X. and Hilber, K. "The anti-addiction drug ibogaine and the heart: a delicate relation." Molecules, 2015.
• Noller, G. E. et al. "Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study." American Journal of Drug and Alcohol Abuse, 2018.

Considering ibogaine treatment? Every patient at Ibogaine Center Cancún starts with a confidential medical screening, including a cardiac review. Start your screening.